0
0
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, has announced that it will begin distributing its NanoBone range of products in the UK.
The product range comprises NanoBone SBX Putty and NanoBone QD, the next-generation synthetic bone grafts that provide reliable early osteogenesis and bone formation.
The launch in the UK coincides with Biocomposites’ attendance at the British Orthopaedic Association’s Annual Congress 2024, which will be held from 17 to 20 September 2024 at the International Convention Centre in Birmingham. Biocomposites is a Platinum Sponsor of this year’s BOA congress and will host Stand #17.
Biocomposites: A Global Force in Infection Prevention and Treatment
Biocomposites is an international medical device company that engineers, manufactures, and markets world-leading products for infection management in bone and soft tissue. Based in Keele, UK, the brand has global operations across Europe, South America, the USA, Canada, China and India.
The brand is a world leader in developing innovative calcium compounds for surgical use. Its products regenerate bone and target infection risks across various specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites products are used in over 1 million procedures annually and sold in more than 100 countries worldwide.
NanoBone: Revolutionising Bone Regeneration
NanoBone’s patented technology consists of nanostructured hydroxyapatite embedded in a silica gel matrix suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration, providing a comparable healing rate to autograft and osteoinductive properties but without the costs and complications of harvesting. NanoBone is preloaded and ready-to-use in various applications to maximise flexibility and efficiency during procedures.
NanoBone, a pioneering bone graft substitute, is now part of Biocomposites GmbH. A leading manufacturer of innovative orthopaedic, spine, foot and ankle, and dental implants, Biocomposites acquired NanoBone last year. Since then, they’ve successfully integrated the NanoBone range into their global distribution network, making it accessible to more surgeons and patients worldwide.
Dr. Walter Gerike, Managing Director of Biocomposites GmbH, said, “NanoBone is a proven technology that has already helped over 100,000 patients throughout the world. The UK is a significant market, and we are very pleased to start selling our innovative range of ready-to-use products there. This development furthers Biocomposites’ position as the go-to provider for surgeons requiring advanced bone regeneration materials.
Visit biocomposites.com to learn more about the brand and its world-leading products.
